Maravai LifeSciences subsidiaries TriLink BioTechnologies and Alphazyme have jointly introduced CleanScribe RNA Polymerase, a novel enzyme designed to significantly reduce the formation of double-stranded RNA (dsRNA) during in vitro transcription (IVT) of mRNA. This innovation aims to enhance the safety and efficacy of mRNA-based therapeutics.
 
dsRNA is an unwanted byproduct of IVT that can trigger adverse inflammatory responses in host cells. CleanScribe RNA Polymerase, a novel DNA-dependent RNA polymerase, catalyzes IVT while drastically reducing dsRNA formation by up to 85% compared to traditional T7 RNA Polymerase.
 
“In this era of mRNA-based medicine, drug developers must streamline their supply chain to remain agile and keep up with demand,” said Justin Barbosa, VP and General Manager of TriLink Discovery. “The integration of high-performing IVT enzymes, mRNA capping analogs, and modified nucleotides are must-haves in mRNA manufacturing.”
 
Researchers can easily integrate CleanScribe RNA Polymerase into their existing IVT protocols, benefiting from its robustness, reproducibility, and superior dsRNA reduction. The enzyme is well-suited for various applications, including mRNA synthesis, saRNA synthesis, radiolabeled RNA probe preparation, and RNA construct development.
 
“We’re thrilled to have had the opportunity to work with TriLink on the launch of CleanScribe RNA Polymerase,” shared Chad Decker, VP and General Manager at Alphazyme. “You can’t produce high-quality mRNA-based therapeutics without high-quality raw material, which is why the potential impact of this IVT enzyme on the field is so exciting.”

Related News